ZMK

Molecule in Development
LBT molecule

Lung Cancer

Lung cancer is one of the most common and severe types of cancer, totaling 1 in 5 cancer deaths worldwide. Three types of lung cancer may be distinguished, i.e. Small Cell Lung Cancer (SCLC), Lung Carcinoid Tumor (LCT) and Non-Small Cell Lung Cancer (NSCLC), the later being the most frequent lung cancer. Squamous cell carcinoma, adenocarcinoma, and large cell carcinoma are all subtypes of NSCLC.

Today, clinicians use different exams to diagnose and stage the disease, combining liquid biopsy and/or brain MRI (Magnetic Resonance Imaging) and/or PET/FDG imaging. Still, PET/FDG imaging’s low specificity does not allow the characterization of tumor cells, which is an issue for clinicians when deciding which personalized targeted treatments are needed.

PET/ZMK imaging allows the visualization of EGFR (Epidermal Growth Factor Receptor) mutations in NSCLC adenocarcinoma lung cancers and can thus guide clinicians in choosing efficient targeted treatments for NSCLC adenocarcinoma lung cancers.

Population

  • Mutated EGFR patients with NSCLC adenocarcinoma lung cancers

Epidemiology

  • US lung cancer prevalence (5 years) : 300k, of which 80% NSCLC, of which 70% adenocarcinoma
  • France lung cancer prevalence (5 years) : 60k, of which 80% NSCLC, of which 70% adenocarcinoma

Next Generation Cdx Pipeline for Molecular
Imaging

Find out more about what’s coming in CDx imaging